touchIMMUNOLOGY were delighted to talk with Professor Marcus Maurer (Charité – Universitätsmedizin Berlin, Berlin, Germany) at EAACI 2021 to discuss the Phase 1a study of CDX-0159 in patients with chronic inducible urticaria.
Questions
- What is CDX-0159 and what is the rationale for its use in patients with chronic inducible urticaria? (0:26)
- Could you tell us a little about the Phase 1a study and its findings? (1:24)
- What will be the next steps in the clinical development of CDX-0159? (2:35)
Disclosures: In relation to this video interview, MM has received honoraria for advice as well as institutional research support by Blueprint and Celldex.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2021 EAACI Annual Meeting.
